Careers
Together,
we can accomplish more.
If you’re patient focused, passionate about what you do, and have an entrepenuerial spirit, you might be interested in learning more about working with us.
Explore Renibus’ career opportunities:
Join Our Team
Sorry, there are no jobs available at this time.
About Renibus Therapeutics
Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients’ lives by developing products to prevent disease progression and improve outcomes associated with cardio, renal and metabolic diseases.
Renibus’ lead program, Veverimer, is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. Veverimer is in Phase 3 development for the treatment of patients with chronic kidney disease and metabolic acidosis.
Veverimer has also received an orphan drug designation for anti-glomerular basement membrane disease (anti-GBM) which could enable an orphan drug development strategy in the future. There may be additional indications beyond anti-GBM where Veverimer’s mechanism of action as a hydrochloric acid binder within the gastrointestinal tract may provide benefit in treating orphan diseases with an unmet medical need.